Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes

Antiviral Research

Volumn 84, Issue 2, 2009, Pages 142-149

  Clayton, Reginald ^a   Ohagen, Asa ^a   Nicol, Francois ^b   Del Vecchio, Alfred M ^c   Jonckers, Tim H M ^a   Goethals, Olivia ^a   Van Loock, Marnix ^a   Michiels, Lieve ^a   Grigsby, John ^b   Xu, Zheng ^b   Zhang, Yuan Peng ^b   Gutshall, Lester L ^c   Cunningham, Mark ^c   Jiang, Haiyan ^c   Bola, Sharon ^c   Sarisky, Robert T ^c   Hertogs, Kurt ^a  

^a TIBOTEC BVBA   (Belgium)

^b ALZA CORPORATION   (United States)

^c CENTOCOR INC   (United States)

Author keywords

F105; HIV 1; Immunoliposome; Pegylated liposome; Protease inhibitor; Targeted therapy

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F105; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ENCAPSULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

ANTI-HIV AGENTS; CELL LINE; DRUG CARRIERS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPOSOMES; POLYETHYLENE GLYCOLS; T-LYMPHOCYTES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70349466520     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.08.003     Document Type: Article

References (38)

1. Abra R.M., Bankert R.B., Chen F., Egilmez N.K., Huang K., Saville R., Slater J.L., Sugano M., and Yokota S.J. The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically stabilized immunoliposomes and active-loading gradients. J. Liposome Res. 12 (2002) 1-3
2. Allen T.M., Austin G.A., Chonn A., Lin L., and Lee K.C. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim. Biophys. Acta 1061 (1991) 56-64
3. Bareford L.M., and Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59 (2007) 748-758
4. Bartlett G.R. Phosphorus assay in column chromatography. J. Biol. Chem. 234 (1959) 466-468
5. Blot G., Janvier K., Le Panse S., Benarous R., and Berlioz-Torrent C. Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for env incorporation into virions and infectivity. J. Virol. 77 (2003) 6931-6945
6. Blume G., and Cevc G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta 1029 (1990) 91-97
7. Bolotin E.M., Cohen R., Bar L.K., Emanuel N., Ninio S., Lasic D.D., and Barenholz Y. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J. Liposome Res. 4 (1994) 455-479
8. Cavacini L.A., Emes C.L., Power J., Duval M., and Posner M.R. Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization. J. Immunol. 152 (1994) 2538-2545
9. Clayton R., Ohagen A., Goethals O., Smets A., Van Loock M., Michiels L., Kennedy-Johnston E., Cunningham M., Jiang H., Bola S., Gutshall L., Gunn G., Del Vecchio A., Sarisky R., Hallenberger S., and Hertogs K. Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells. J. Virol. Methods 139 (2007) 17-23
10. Cosson P., and Letourneur F. Coatomer (COPI)-coated vesicles: role in intracellular transport and protein sorting. Curr. Opin. Cell Biol. 9 (1997) 484-487
11. De Kock, H.A., Jonckers, T.H.M., Last, S.J., Boonants, P.M.J.G., Surleraux, D.L.N.G. and Wigerinck, P.B.T.P., 2006. Substituted aminophenylsulfonamide compounds as HIV protease inhibitor. PCT Int. Appl. WO2007060253 A1.
12. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51 (1999) 691-743
13. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
14. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5 (2005) 161-171
15. Fisher K.J., and Wilson J.M. The transmembrane domain of diphtheria toxin improves molecular conjugate gene transfer. Biochem. J. 321 (1997) 49-58
16. Flasher D., Konopka K., Chamow S.M., Dazin P., Ashkenazi A., Pretzer E., and Düzgünes N. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochim. Biophys. Acta 1194 (1994) 185-196
17. Gabizon A., Shmeeda H., and Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42 (2003) 419-436
18. Gabizon A.A., Barenholz Y., and Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res. 10 (1993) 703-708
19. Gagné J.-F., Désormeaux A., Perron S., Tremblay M.J., and Bergeron M.G. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim. Biophys. Acta 1558 (2002) 198-210
20. Geeraert L., Kraus G., and Pomerantz R.J. Hide-and-Seek: the challenge of viral persistence in HIV-1 infection. Annu. Rev. Med. 59 (2008) 487-501
21. Guillemont J., Pasquier E., Palandjian P., Vernier D., Gaurrand S., Lewi P.J., Heeres J., de Jonge M.R., Koymans L.M.H., Daeyaert F.F.D., Vinkers M.H., Arnold E., Das K., Pauwels R., Andries K., de Béthune M.-P., Bettens E., Hertogs K., Wigerinck P., Timmerman P., and Janssen P.A. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J. Med. Chem. 48 (2005) 2072-2079
22. Haicheur N., Bismuth E., Bosset S., Adotevi O., Warnier G., Lacabanne V., Regnault A., Desaymard C., Amigorena S., Ricciardi-Castagnoli P., Goud B., Fridman W.H., Johannes L., and Tartour E. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J. Immunol. 165 (2000) 3301-3308
23. Ivens T., Van den Eynde C., Van Acker K., Nijs E., Dams G., Bettens E., Ohagen A., Pauwels R., and Hertogs K. Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus. J. Virol. Methods 129 (2005) 56-63
24. Jochmans D., Deval J., Kesteleyn B., Van Marck H., Bettens E., De Baere I., Dehertogh P., Ivens T., Van Ginderen M., Van Schoubroeck B., Ehteshami M., Wigerinck P., Götte M., and Hertogs K. Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. J. Virol. 80 (2006) 12283-12292
25. Klibanov A.L., Maruyama K., Torchilin V.P., and Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268 (1990) 235-237
26. Lukyanov A.N., Elbayoumi T.A., Chakilam A.R., and Torchilin V.P. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Control. Release 100 (2004) 135-144
27. Mishra V., Mahor S., Rawat A., Gupta P.N., Dubey P., Khatri K., and Vyas S.P. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J. Drug Target. 14 (2006) 45-53
28. Montessori V., Press N., Harris M., Akagi L., and Montaner J.S.G. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170 (2004) 229-238
29. Parkkinen J.J., Lammi M.J., Ågren U., Tammi M., Keinänen T.A., Hyvönen T., and Eloranta T.O. Polyamine-dependent alterations in the structure of microfilaments, Golgi apparatus, endoplasmic reticulum, and proteoglycan synthesis in BHK cells. J. Cell. Biochem. 66 (1997) 165-174
30. Pomerantz R.J., and Horn D.L. Twenty years of therapy for HIV-1 infection. Nat. Med. 9 (2003) 867-873
31. Posner M.R., Hideshima T., Cannon T., Mukherjee M., Mayer K.H., and Byrn R.A. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146 (1991) 4325-4332
32. Pretzer E., Flasher D., and Duzgunes N. Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689, 502, an inhibitor of the viral protease. Antiviral Res. 34 (1997) 1-15
33. Slepushkin V.A., Salem I.I., Andreev S.M., Dazin P., and Duzgunes N. Targeting of liposomes to HIV-1-infected cells by peptides derived from the CD4 receptor. Biochem. Biophys. Res. Commun. 227 (1996) 827-833
34. Song E., Zhu P., Lee S.-K., Chowdhury D., Kussman S., Dykxhoorn D.M., Feng Y., Palliser D., Weiner D.B., Shankar P., Marasco W.A., and Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23 (2005) 709-717
35. Stenmark H., Moskaug J.O., Madshus I.H., Sandvig K., and Olsnes S. Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol. J. Cell Biol. 113 (1991) 1025-1032
36. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
37. UNAIDS, 2008. 2008 Report on the global AIDS epidemic. Online at http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp.
38. Vetterlein M., Ellinger A., Neumuller J., and Pavelka M. Golgi apparatus and TGN during endocytosis. Histochem. Cell Biol. 117 (2002) 143-150